TMDX icon

Transmedics

121.58 USD
At close May 16, 4:00 PM EDT
After hours
118.05
-3.53
2.90%
1 day
0.00%
5 days
0.00%
1 month
0.00%
3 months
0.00%
6 months
0.00%
Year to date
0.00%
1 year
0.00%
5 years
635.51%
10 years
443.74%
 

About: TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Employees: 728

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

49% more repeat investments, than reductions

Existing positions increased: 125 | Existing positions reduced: 84

1.14% more ownership

Funds ownership: 108.63% [Q3] → 109.78% (+1.14%) [Q4]

16% less funds holding

Funds holding: 365 [Q3] → 308 (-57) [Q4]

17% less call options, than puts

Call options by funds: $51.6M | Put options by funds: $62.5M

40% less first-time investments, than exits

New positions opened: 73 | Existing positions closed: 122

59% less capital invested

Capital invested by funds: $5.67B [Q3] → $2.3B (-$3.37B) [Q4]

90% less funds holding in top 10

Funds holding in top 10: 10 [Q3] → 1 (-9) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$104
14%
downside
Avg. target
$120
2%
downside
High target
$130
7%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Oppenheimer
Suraj Kalia
56% 1-year accuracy
10 / 18 met price target
7%upside
$130
Outperform
Maintained
9 May 2025
Piper Sandler
Matt O'Brien
50% 1-year accuracy
24 / 48 met price target
3%upside
$125
Overweight
Reiterated
9 May 2025
Canaccord Genuity
William Plovanic
43% 1-year accuracy
20 / 47 met price target
14%downside
$104
Buy
Maintained
11 Mar 2025

Financial journalist opinion

Based on 29 articles about TMDX published over the past 30 days

Positive
Zacks Investment Research
1 day ago
Earnings Estimates Moving Higher for TransMedics (TMDX): Time to Buy?
TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Earnings Estimates Moving Higher for TransMedics (TMDX): Time to Buy?
Positive
Zacks Investment Research
1 day ago
What Makes TransMedics (TMDX) a New Buy Stock
TransMedics (TMDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes TransMedics (TMDX) a New Buy Stock
Neutral
Accesswire
2 days ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Reach Out
Positive
The Motley Fool
3 days ago
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years
While being an innovative company doesn't guarantee superior long-term returns, it doesn't hurt those chances either. In fact, when a corporation is making important breakthroughs and boasts significant growth prospects in its industry, that could translate to above-average stock market performances over five years or more.
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years
Neutral
Accesswire
4 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Shareholders to Learn More About the Investigation
Positive
The Motley Fool
4 days ago
TransMedics Group Stock Is Up 81% in 2025. Can It Climb Even Higher?
Shares of TransMedics Group (TMDX 6.54%) recently bounded higher in response to a first-quarter earnings report that was a lot better than investors were expecting. Downward revenue guidance revisions and unwanted attention from short-sellers pushed the stock down late last year, but things are looking up.
TransMedics Group Stock Is Up 81% in 2025. Can It Climb Even Higher?
Neutral
Accesswire
6 days ago
TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Positive
Zacks Investment Research
1 week ago
TMDX Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down
Increased organ utilization in liver and continued OCS adoption across both liver and heart boosted TransMedics' first-quarter 2025 performance.
TMDX Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down
Positive
The Motley Fool
1 week ago
Why TransMedics Stock Is Skyrocketing Today
Shares of next-generation transplant technology platform TransMedics (TMDX 21.72%) were up 21% as of noon ET on Friday, according to data provided by S&P Global Market Intelligence.
Why TransMedics Stock Is Skyrocketing Today
Positive
Investors Business Daily
1 week ago
Former Highflier TransMedics Catapults To Seven-Month High On Liver-Driven Beat
TransMedics stock rocketed Friday after the company beat Wall Street's first-quarter expectations and hiked its 2025 revenue guidance.
Former Highflier TransMedics Catapults To Seven-Month High On Liver-Driven Beat
Charts implemented using Lightweight Charts™